Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Reuters

Sep 04

Pelthos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2564300314"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564300314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564300314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564300314","market":"us","top_or_hot":-1,"title":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pelthos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 04:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pelthos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTHS","symbol_name":"PELTHOS THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL7K5rvN:1","article_id":"2564300314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564300314","pubTimestamp":1756932625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTHS":"PELTHOS THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Pelthos Therapeutics Inc.发布投资者演示文稿，重点介绍用于传染性软疣治疗的Zelsuvmi的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTHS":0.9},"content_text":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    \n\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}